150 related articles for article (PubMed ID: 6357802)
21. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
Durie BG; Stock-Novack D; Salmon SE; Finley P; Beckord J; Crowley J; Coltman CA
Blood; 1990 Feb; 75(4):823-30. PubMed ID: 2405920
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.
Kantarjian HM; Smith T; Estey E; Polyzos A; O'Brien S; Pierce S; Beran M; Feldman E; Keating MJ
Am J Med; 1992 Dec; 93(6):599-604. PubMed ID: 1466355
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter.
Boccadoro M; Omedè P; Frieri R; Battaglio S; Gallone G; Massaia M; Redoglia V; Pileri A
Acta Haematol; 1989; 82(3):122-5. PubMed ID: 2510433
[TBL] [Abstract][Full Text] [Related]
24. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
MacLennan IC; Chapman C; Dunn J; Kelly K
Lancet; 1992 Jan; 339(8787):200-5. PubMed ID: 1346171
[TBL] [Abstract][Full Text] [Related]
25. Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
Norfolk D; Child JA; Cooper EH; Kerruish S; Ward AM
Br J Cancer; 1980 Oct; 42(4):510-5. PubMed ID: 6159910
[TBL] [Abstract][Full Text] [Related]
26. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
[TBL] [Abstract][Full Text] [Related]
28. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
29. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
Iakovleva SV; Andreeva NE; Izgorodin AS
Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
[TBL] [Abstract][Full Text] [Related]
30. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
31. Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Shimizu K; Kamiya O; Hirabayashi N; Ichikawa A; Kawashima K; Kobayashi M; Mizuno H; Nagura E; Nitta M; Saito H; Sao H; Shibata T; Takeyama H
Jpn J Cancer Res; 1999 Mar; 90(3):355-60. PubMed ID: 10359052
[TBL] [Abstract][Full Text] [Related]
32. [Serum ferritin and beta-2-microglobulin in multiple myeloma].
Linkesch W; Ludwig H
Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172
[TBL] [Abstract][Full Text] [Related]
33. [Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma].
Bataille R; Grenier J
Presse Med; 1986 Oct; 15(34):1723-5. PubMed ID: 2947132
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
Cuzick J; Cooper EH; MacLennan IC
Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
[TBL] [Abstract][Full Text] [Related]
35. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
36. [Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma].
Takagi T; Oguro M; Sakai C
Rinsho Ketsueki; 1986 Dec; 27(12):2249-53. PubMed ID: 3471977
[No Abstract] [Full Text] [Related]
37. Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins?
Bataille R; Klein B
Blood; 1991 Apr; 77(7):1616-7. PubMed ID: 1706956
[No Abstract] [Full Text] [Related]
38. Alpha interferon raises serum beta-2-microglobulin in patients with multiple myeloma.
Tienhaara A; Remes K; Pelliniemi TT
Br J Haematol; 1991 Mar; 77(3):335-8. PubMed ID: 2012758
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
40. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.
Linkesch W; Ludwig H
Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
